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CLUSIONS: Loss of HBeAg is responsive to dose and duration
in the treatment with interferon-a. A high-dose (≥5MU) and
regular-duration (16–24 weeks) interferon-a is effective than in
clearing virological and serological markers. A dose ≥5MU and
a duration 16–24 week interferon-a is recommended to use.
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OBJECTIVES: The gastrointestinal (GI) risks associated with
selective cyclooxygenase-2 inhibitors (COX-2s) versus non-
selective non-steroidal anti-inﬂammatory drugs (NSAIDs)
among arthritis patients are well documented in clinical trials.
This study is to estimate the major GI risks among elderly
chronic users of COX-2s versus NSAIDs, with/without aspirin
(ASA), in clinical practice. METHODS: A cohort study was con-
ducted using secondary data from the GE logician database
(Centricity EMR), which contained medical records of 3 million
patients seen by 5,000 physicians across 27 states. Inclusion cri-
teria: chronic use (2 or more medication mentions) of COX-2s
or NSAIDs within 60 days between 1/1/1999 and 6/30/2003, 65
or older, no switch between COX-2s and NSAIDs during one-
year follow-up or before a major GI event, deﬁned as GI hem-
orrhage including melena (ICD-9 codes: 578.xx). Descriptive
and multivariate logistic analyses were conducted to determine
how major GI risks differed across chronic users of COX-2s
alone, NSAIDs alone, COX-2s + ASA, and NSAIDs + ASA. The
logistic analysis controlled for gender, age, pre- or post-index GI-
harmful drug use, major and minor GI events in the year prior
to index date, and prior GI-protective drug use. RESULTS: The
number of patients and the percent having major GI events
during one-year follow-up period were as follows: COX-2s-
alone 7,338 (1.73%); NSAIDs-alone 3,826 (2.06%); COX-2s +
ASA 963 (1.77%); and NSAIDs + ASA 602 (2.66%). The mul-
tivariate logistic results showed that compared to COX-2s-alone
users, NSAIDs-alone and NSAIDs + ASA users had higher major
GI risks (OR = 1.35, p = 0.04, 95% CI: 1.01–1.80; and OR =
1.68, p = 0.06, 95% CI: 0.99–2.86 respectively). COX-2s + ASA
users had similar risks (OR = 0.96, p = 0.88, 95% CI: 0.57–1.61)
to COX-2s-alone users. CONCLUSIONS: The major GI risk
was highest among elderly chronic users of NSAIDs + ASA, fol-
lowed by NSAIDs-alone. Only NSAIDs-alone users had a statis-
tically signiﬁcant higher risk than COX-2s-alone users. The
addition of ASA did not signiﬁcantly increase major GI risk
among COX-2 users.
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OBJECTIVES: Few trials directly compared lamivudine with
adefovir in patients with HBeAg-positive and HBeAg-negative
chronic hepatitis B (CHB). This study used direct and indirect
comparison methods to compare the relative efﬁcacy of lamivu-
dine to adefovir. METHODS: We searched Medline, SCI-
expanded, Current Content Connect, Cochrane Library and
Chinese Biomedical Database to September 15, 2005, and man-
ually screened the references of included studies. Trials for
HBeAg-positive and HBeAg-negative CHB were included if they
directly compared lamivudine with adefovir, or compared
lamivudine (or adefovir) with placebo/non-treatment. Direct
comparison was made by pooling the trials of lamivudine versus
adefovir. An adjusted indirect comparison was performed by 
calculating the difference of pooled estimates of lamivudine and
adefovir, which was obtained from trials of lamivudine (or 
adefovir) versus placebo/no treatment. RESULTS: Eight trials 
(n = 1324) were included. Of these, six were trials for HBeAg-
positive CHB patients, and two for HBeAg-negative CHB
patients. One trial compared lamivudine with adefovir in lamivu-
dine-resistant patients with HBeAg-positive CHB, and seven
trials compared lamivudine (or adefovir) with placebo/non-treat-
ment in naïve patients. Quality was medium-to-high in most
trials. The direct comparison for lamivudine-resistant patients
showed that lamivudine with adefovir were equivalent in clear-
ing serological markers, lamivudine was less effective in nor-
malizing ALT (OR = 0.11, 95%CI = 0.013–0.97) but superior
in histological response (OR = 2.08, 95%CI = 1.08–4.04). Indi-
rect comparison from four trials (n = 915) showed that lamivu-
dine and adefovir were equally effective in serological and
biomedical markers in naïve patients with HBeAg-positive CHB.
Indirect comparison from two trials (n = 282) showed that
lamivudine was more effective in normalization of ALT than 
adefovir in HBeAg-negative CHB. But no data on serological and
histological response were available. CONCLUSION: Lamivu-
dine and adefovir was equally effective for naïve patients with
HBeAg-positive CHB. Larger direct comparison trials for




COMPARING THE COST-EFFECTIVENESS OF THE
INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF
CHRONIC HEPATITIS C VIRUS (HCV): A MODEL EVALUATING
THE CLINICAL AND ECONOMIC IMPACT OF CURRENT
TREATMENT OPTIONS
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OBJECTIVES: The interferons (IFNs) currently indicated for the
treatment of chronic Hepatitis C Virus (HCV) have been shown
to exhibit varying responsiveness in terms of achieving a sus-
tained viral response (SVR). It is the objective of this model to
be used as tool to compare the relative cost-effectiveness of these
agents from a payer perspective. METHODS: An interactive
Excel-based model was developed to compare the relative cost
of treating chronic HCV in terms of both treatment naïve and
pegylated-IFN nonresponders. Drug effectiveness with respect to
the SVR rate was based on the published literature for therapy
in combination with weight-based ribavirin. Drug costs were
based on average wholesale price cost with consideration of con-
tractual discounts and patient co-payment. The primary eco-
nomic endpoint was the drug cost per SVR obtained. Results
were displayed for treatment naïve, pegylated-IFN nonrespon-
ders, and combined cases respectively. Multi-factor sensitivity
analyses were conducted. RESULTS: In a typical managed care
population, with an estimated prevalence of chronic HCV of
1.4% and with 5% of patients being treated, the drug cost of
HCV treatment is $1.22 PMPM. For treatment naïve patients,
Genotype I, the cost per SVR obtained is $31,356, $51,152, and
$19,113 for Pegasys, Peg-Intron, and consensus interferon
(CIFN) respectively. For treatment naïve patients, Genotypes 2/3,
the cost per SVR obtained is $18,030, $24,890, and $12,305 for
